<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653417</url>
  </required_header>
  <id_info>
    <org_study_id>VMRAD1901-203</org_study_id>
    <nct_id>NCT02653417</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to determine the clinical safety of RAD1901 and to
      evaluate whether RAD1901 reduced the frequency and severity of moderate to severe vasomotor
      symptoms (VMS; &quot;hot flashes&quot;) in postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2b outpatient, prospective, multicenter, double-blind, randomized,
      placebo-controlled study to determine whether elacestrant reduces the frequency and severity
      of vasomotor symptoms (VMS; &quot;hot flashes&quot;) in postmenopausal women with moderate to severe
      hot flashes. Postmenopausal women who met study criteria were followed for 12 weeks on
      double-blind study medication and two weeks off study medication.

      Treatment was randomized 1:1:1:1 to ensure that an approximately equal number of patients
      were exposed to each of three RAD1901 (elacestrant) doses (5, 10 and 20 mg/day) or placebo.
      The total period of placebo exposure was 14 weeks.

      Enrolling approximately 300 patients was expected to provide power for testing superiority of
      the primary efficacy endpoint outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's Decision
  </why_stopped>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 12, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in the Frequency of Moderate to Severe Hot Flashes</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline to week 12 in the average number of moderate and severe hot flashes per day, where change is calculated as week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.
Severity of hot flashes was self-assessed and reported as follows:
Mild: sensation of heat without sweating
Moderate: sensation of heat with sweating, able to continue activity
Severe: sensation of heat with sweating, causing cessation of activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in the Frequency of Moderate to Severe Hot Flashes</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change from baseline to week 4 in the average number of moderate and severe hot flashes per day, where change is calculated as week 4 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 and Week 12 in the Severity of Hot Flashes</measure>
    <time_frame>Baseline, 4 weeks, and 12 weeks</time_frame>
    <description>Change from baseline to week 4 and week 12 in the average daily severity of hot flashes, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash severity.
Subjects recorded the number of hot flashes per day using an electronic diary. Daily severity score for hot flashes for each subject was calculated as the sum of the number of mild hot flashes, plus 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of mild, moderate, and severe hot flashes. That is,
Daily Severity Score = (Fmild + 2•Fmod + 3•Fsev)/(Fmild + Fmod + Fsev) where Fmild= frequency of mild hot flashes, Fmod = frequency of moderate hot flashes, Fsev = frequency of severe hot flashes.
The measure is a weighted average of the frequencies of Hot Flashes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 and Week 12 in the Frequency of All Hot Flashes</measure>
    <time_frame>Baseline, 4 weeks, and 12 weeks</time_frame>
    <description>Change from baseline to week 4 and week 12 in the average number of all hot flashes (mild, moderate, and severe) by eDiary, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Vasomotor Symptoms</condition>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD1901 5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD1901 10 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD1901 20 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD1901</intervention_name>
    <description>RAD1901</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_label>Regimen 3</arm_group_label>
    <other_name>Elacestrant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Regimen 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To have participated in this study, a subject MUST:

          1. be a postmenopausal woman between 40 and 65 years of age, inclusive

          2. be seeking relief or treatment for moderate to severe VMS

          3. be willing to discontinue and abstain from the following: vaginal hormonal products;
             transdermal or oral estrogen or estrogen/progestin combination; progestin implants;
             injectable estrogen; topical progesterone cream, selective estrogen receptor
             modulators and intrauterine devices (IUDs)

          4. have no clinically significant abnormalities on pelvic exam except for vulvovaginal
             atrophy (VVA)

          5. have a normal or clinically insignificant transvaginal ultrasound (TVU) with an
             endometrial thickness &lt;4 mm at screening

          6. have a normal endometrial biopsy subsequent to the TVU without clinically relevant
             results

          7. have a normal screening Papanicolaou (Pap) smear

          8. have a mammogram within 9 months prior to randomization. Subjects must have had a
             Breast Imaging Reporting and Data System (BI-RADS) mammography result of 1 or 2 to
             enroll.

        Exclusion Criteria:

        Subjects with any of the following characteristics were not be eligible to participate in
        the study:

          1. have a history of invasive breast cancer or ductal carcinoma in situ, melanoma or any
             gynecologic cancer.

          2. using any of the following:

               -  oral estrogen-, progestin-, androgen-, or selective estrogen receptor modulator
                  (SERM) containing drug products within 8 weeks before screening (visit 1)

               -  transdermal hormone products within 4 weeks before screening (visit 1)

               -  vaginal hormone products (rings, creams, gels) within 4 weeks before screening
                  (visit 1)

               -  progestin implants/injectables, IUDs or estrogen pellets/injectables within 6
                  months before screening (visit 1)

               -  anabolic steroids

          3. have been treated with a gonadotropin-releasing hormone (GnRH) agonist within the last
             year

          4. have been treated with anti-estrogens or aromatase inhibitors within 2 months prior to
             study entry

          5. have been concurrently treated and will abstain from gabapentin and paroxetine or
             serotonin and norepinephrine reuptake inhibitors (SNRIs) for VMS or other indications
             for 3 months during the trial and have not taken within 4 weeks prior to screening

          6. have unexplained vaginal bleeding within the 3 months prior to study entry

          7. have an endometrial biopsy at baseline with a diagnosis by a gynecologic pathologist
             of proliferative, hyperplasia, polyp or cancer

          8. have unresolved cervical cytological smear report of atypical glandular or squamous
             cells of undetermined significance. Cervical cytologic smear report of ASCUS, low
             grade squamous intraepithelial lesion or greater, or any reported dysplasia

          9. have unresolved findings suspicious for malignancy on the breast examination
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Operations</last_name>
    <role>Study Director</role>
    <affiliation>Radius Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Health Care Specialists P.C. - Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <results_first_submitted>October 15, 2018</results_first_submitted>
  <results_first_submitted_qc>March 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2019</results_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Regimen 1</title>
          <description>RAD1901 5 mg
RAD1901: RAD1901</description>
        </group>
        <group group_id="P2">
          <title>Regimen 2</title>
          <description>RAD1901 10 mg
RAD1901: RAD1901</description>
        </group>
        <group group_id="P3">
          <title>Regimen 3</title>
          <description>RAD1901 20 mg
RAD1901: RAD1901</description>
        </group>
        <group group_id="P4">
          <title>Regimen 4</title>
          <description>Placebo
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>mITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Regimen 1 RAD1901 5 mg</title>
          <description>RAD1901 5 mg
RAD1901: RAD1901</description>
        </group>
        <group group_id="B2">
          <title>Regimen 2 RAD1901 10 mg</title>
          <description>RAD1901 10 mg
RAD1901: RAD1901</description>
        </group>
        <group group_id="B3">
          <title>Regimen 3 RAD1901 20 mg</title>
          <description>RAD1901 20 mg
RAD1901: RAD1901</description>
        </group>
        <group group_id="B4">
          <title>Regimen 4 Placebo</title>
          <description>Placebo
Placebo: Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="38"/>
            <count group_id="B5" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="4.83"/>
                    <measurement group_id="B2" value="55.4" spread="5.08"/>
                    <measurement group_id="B3" value="54.1" spread="4.07"/>
                    <measurement group_id="B4" value="53.9" spread="5.09"/>
                    <measurement group_id="B5" value="55.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in the Frequency of Moderate to Severe Hot Flashes</title>
        <description>Change from baseline to week 12 in the average number of moderate and severe hot flashes per day, where change is calculated as week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.
Severity of hot flashes was self-assessed and reported as follows:
Mild: sensation of heat without sweating
Moderate: sensation of heat with sweating, able to continue activity
Severe: sensation of heat with sweating, causing cessation of activity.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>The modified intent to treat (mITT) population was used. This included all patients in the safety population who had recorded hot flash data in their eDiaries for at least 5 days during baseline and for at least one day while on double-blind study medication, and was the primary analysis population for all efficacy analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1</title>
            <description>RAD1901 5 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2</title>
            <description>RAD1901 10 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3</title>
            <description>RAD1901 20 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O4">
            <title>Regimen 4</title>
            <description>Placebo
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in the Frequency of Moderate to Severe Hot Flashes</title>
          <description>Change from baseline to week 12 in the average number of moderate and severe hot flashes per day, where change is calculated as week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.
Severity of hot flashes was self-assessed and reported as follows:
Mild: sensation of heat without sweating
Moderate: sensation of heat with sweating, able to continue activity
Severe: sensation of heat with sweating, causing cessation of activity.</description>
          <population>The modified intent to treat (mITT) population was used. This included all patients in the safety population who had recorded hot flash data in their eDiaries for at least 5 days during baseline and for at least one day while on double-blind study medication, and was the primary analysis population for all efficacy analyses</population>
          <units>moderate to severe hot flashes per day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.48" spread="0.793"/>
                    <measurement group_id="O2" value="-3.74" spread="0.867"/>
                    <measurement group_id="O3" value="-4.12" spread="0.944"/>
                    <measurement group_id="O4" value="-3.66" spread="0.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Regimen 1 = 5 mg vs Regimen 4 = placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.18</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Regimen 2 = 10 mg vs Regimen 4 = placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Regimen 3 = 20 mg vs Regimen 4 = placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.46</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in the Frequency of Moderate to Severe Hot Flashes</title>
        <description>Change from baseline to week 4 in the average number of moderate and severe hot flashes per day, where change is calculated as week 4 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1 RAD1901 5 mg</title>
            <description>RAD1901 5 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2 RAD1901 10 mg</title>
            <description>RAD1901 10 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3 RAD1901 20 mg</title>
            <description>RAD1901 20 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O4">
            <title>Regimen 4 Placebo</title>
            <description>Placebo
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in the Frequency of Moderate to Severe Hot Flashes</title>
          <description>Change from baseline to week 4 in the average number of moderate and severe hot flashes per day, where change is calculated as week 4 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.</description>
          <population>mITT population</population>
          <units>moderate to severe hot flashes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="3.644"/>
                    <measurement group_id="O2" value="-2.22" spread="4.872"/>
                    <measurement group_id="O3" value="-2.70" spread="3.764"/>
                    <measurement group_id="O4" value="-3" spread="4.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 and Week 12 in the Severity of Hot Flashes</title>
        <description>Change from baseline to week 4 and week 12 in the average daily severity of hot flashes, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash severity.
Subjects recorded the number of hot flashes per day using an electronic diary. Daily severity score for hot flashes for each subject was calculated as the sum of the number of mild hot flashes, plus 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of mild, moderate, and severe hot flashes. That is,
Daily Severity Score = (Fmild + 2•Fmod + 3•Fsev)/(Fmild + Fmod + Fsev) where Fmild= frequency of mild hot flashes, Fmod = frequency of moderate hot flashes, Fsev = frequency of severe hot flashes.
The measure is a weighted average of the frequencies of Hot Flashes.</description>
        <time_frame>Baseline, 4 weeks, and 12 weeks</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1 RAD1901 5 mg</title>
            <description>RAD1901 5 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2 RAD1901 10 mg</title>
            <description>RAD1901 10 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3 RAD1901 20 mg</title>
            <description>RAD1901 20 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O4">
            <title>Regimen 4 Placebo</title>
            <description>Placebo
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 and Week 12 in the Severity of Hot Flashes</title>
          <description>Change from baseline to week 4 and week 12 in the average daily severity of hot flashes, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash severity.
Subjects recorded the number of hot flashes per day using an electronic diary. Daily severity score for hot flashes for each subject was calculated as the sum of the number of mild hot flashes, plus 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of mild, moderate, and severe hot flashes. That is,
Daily Severity Score = (Fmild + 2•Fmod + 3•Fsev)/(Fmild + Fmod + Fsev) where Fmild= frequency of mild hot flashes, Fmod = frequency of moderate hot flashes, Fsev = frequency of severe hot flashes.
The measure is a weighted average of the frequencies of Hot Flashes.</description>
          <population>mITT population</population>
          <units>hot flash severity score per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 change from baseline in severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.25"/>
                    <measurement group_id="O2" value="-0.07" spread="0.26"/>
                    <measurement group_id="O3" value="-0.13" spread="0.273"/>
                    <measurement group_id="O4" value="-0.00" spread="0.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 change from baseline in severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.337"/>
                    <measurement group_id="O2" value="-0.08" spread="0.373"/>
                    <measurement group_id="O3" value="-0.13" spread="0.313"/>
                    <measurement group_id="O4" value="-0.01" spread="0.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 and Week 12 in the Frequency of All Hot Flashes</title>
        <description>Change from baseline to week 4 and week 12 in the average number of all hot flashes (mild, moderate, and severe) by eDiary, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.</description>
        <time_frame>Baseline, 4 weeks, and 12 weeks</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen 1 RAD1901 5 mg</title>
            <description>RAD1901 5 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O2">
            <title>Regimen 2 RAD1901 10 mg</title>
            <description>RAD1901 10 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O3">
            <title>Regimen 3 RAD1901 20 mg</title>
            <description>RAD1901 20 mg
RAD1901: RAD1901</description>
          </group>
          <group group_id="O4">
            <title>Regimen 4 Placebo</title>
            <description>Placebo
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 and Week 12 in the Frequency of All Hot Flashes</title>
          <description>Change from baseline to week 4 and week 12 in the average number of all hot flashes (mild, moderate, and severe) by eDiary, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.</description>
          <population>mITT population</population>
          <units>hot flashes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="3.803"/>
                    <measurement group_id="O2" value="-2.23" spread="4.792"/>
                    <measurement group_id="O3" value="-2.29" spread="3.754"/>
                    <measurement group_id="O4" value="-3.27" spread="4.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.47" spread="5.076"/>
                    <measurement group_id="O2" value="-2.40" spread="3.560"/>
                    <measurement group_id="O3" value="-3.91" spread="5.263"/>
                    <measurement group_id="O4" value="-3.74" spread="4.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Regimen 1 RAD1901 5 mg</title>
          <description>RAD1901 5 mg
RAD1901: RAD1901</description>
        </group>
        <group group_id="E2">
          <title>Regimen 2 RAD1901 10 mg</title>
          <description>RAD1901 10 mg
RAD1901: RAD1901</description>
        </group>
        <group group_id="E3">
          <title>Regimen 3 RAD1901 20 mg</title>
          <description>RAD1901 20 mg
RAD1901: RAD1901</description>
        </group>
        <group group_id="E4">
          <title>Regimen 4 Placebo</title>
          <description>Placebo
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations</name_or_title>
      <organization>Radius Pharmaceuticals, Inc.</organization>
      <phone>617-551-4000</phone>
      <email>clinopsinfo@radiuspharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

